Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

While smokable product sales are declining slowly, sales of non-smokable products are driving growth for Altria Group. The company acquired the NJOY brand in 2023 and it's still one of just three ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...

This release contains forward-looking information about Pfizer Oncology, TALZENNA and XTANDI, including their potential benefits, the TALAPRO-2 results, and potential updates of the approved ...

TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with ...